Trial Profile
Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Gemcitabine (Primary) ; Methylprednisolone (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 13 Jun 2013 Planned end date changed from 1 Jan 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 03 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Jan 2010 Additional location (Canada) identified as reported by ClinicalTrials.gov.